Genocea Biosciences (Genocea) has received a grant from the University of Pittsburgh Medical Center’s (UPMC) sexually transmitted infections (STI) cooperative research center for the development of vaccines for
Celgene has presented clinical data from an investigational Phase IIb, double-blind, placebo-controlled study of Apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis (PSOR-005). The study was a 352-patient,
The FAD has approved the experimental use of Diamyd vaccine in children as young as 3 years of age in the TrialNet GAD study, enrolling 126 new onset
Active Biotech has achieved primary end point in ongoing Phase II clinical trial of TASQ, in patients with asymptomatic, castrate resistant, metastatic prostate cancer. The first analysis of
Intercell and GlaxoSmithKline Biologicals (GSK) will form a strategic alliance to accelerate the development and commercialisation of needle-free, patch-based vaccines. The agreement will include Intercell’s candidate vaccine for
Sanofi-aventis has launched its new production units at the Le Trait site in a ceremony attended by Jean-Marie Aline, Mayor of Le Trait, Christophe Bouillon, Member of the
Takeda and Pronova BioPharma have announced that the advancement of TAK-085 (omega-3 acid ethyl esters 90) for the treatment of hypertriglyceridemia into Phase 3 clinical programs in Japan.
Evotec has received a milestone payment from Ono Pharmaceutical (Ono) from its research collaboration aimed at identifying inhibitors for a protease target. The milestone is received for the
Ipsen reports the preliminary results of a Phase I trial in metastatic breast cancer with BN83495, first-in-class orally available irreversible steroid sulfatase (STS) inhibitor. In the course of
Basilea Pharmaceutica has announced that Toctino (alitretinoin) was recommended for regulatory approval under the repeat-use procedure in 13 additional EU Member States as well as in Norway and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.